Cbd Pain Relief Cream
NDC 62742-4198
Product Information
Cbd Pain Relief Cream (trolamine salicylate) is a OTC MONOGRAPH DRUG-approved product labeled by Allure Labs. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a cream for topical administration. This product entry covers the primary NDC 62742-4198 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 62742-4198?
What are the uses of this product?
What are Active Ingredients of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- TROLAMINE SALICYLATE (UNII: H8O4040BHD)
- SALICYLIC ACID (UNII: O414PZ4LPZ) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- CAPRYLHYDROXAMIC ACID (UNII: UPY805K99W)
- COCONUT ALKANES (UNII: 1E5KJY107T)
- CANNABIDIOL (UNII: 19GBJ60SN5)
- ROSA MOSCHATA SEED OIL (UNII: T031ZE559T)
- VANILLYL BUTYL ETHER (UNII: S2ULN37C9R)
- WATER (UNII: 059QF0KO0R)
- GLYCERYL MONOSTEARATE (UNII: 230OU9XXE4)
- TOCOPHEROL (UNII: R0ZB2556P8)
- COCO-CAPRYLATE/CAPRATE (UNII: 8D9H4QU99H)
- GLYCERYL CAPRYLATE (UNII: TM2TZD4G4A)
- SORBITAN OLIVATE (UNII: MDL271E3GR)
- GLYCERIN (UNII: PDC6A3C0OX)
- DIMETHYL SULFONE (UNII: 9H4PO4Z4FT)
- CETEARYL OLIVATE (UNII: 58B69Q84JO)
- CETOSTEARYL ALCOHOL (UNII: 2DMT128M1S)
- POLYOXYL 20 CETOSTEARYL ETHER (UNII: YRC528SWUY)
- SORBITAN MONOPALMITATE (UNII: 77K6Z421KU)
- XANTHAN GUM (UNII: TTV12P4NEE)
- STEARIC ACID (UNII: 4ELV7Z65AP)
- CETYL PALMITATE (UNII: 5ZA2S6B08X)
* Please review the full disclaimer at the bottom of this page.